<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00064402</url>
  </required_header>
  <id_info>
    <org_study_id>091-051</org_study_id>
    <nct_id>NCT00064402</nct_id>
  </id_info>
  <brief_title>Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD</brief_title>
  <official_title>A Double-Blind, Double-Dummy, Randomized, Placebo- and Active-Controlled, Multicenter, Parallel-Group Study of (R,R)-Formoterol in the Treatment of Subjects With Chronic Obstructive Pulmonary Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the bronchodilator effect and safety of multiple daily
      doses of arformoterol administered for 12 weeks as maintenance treatment in patients with
      COPD
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a double-blind, double-dummy, randomized, placebo- and active-controlled,
      multicenter, parallel-group study of adult subjects with COPD. The study was double blinded
      through the use of both unit dose vial (UDV) and metered-dose inhaler (MDI) placebos, as
      appropriate. The primary efficacy analysis utilized the placebo control. Secondary analyses
      of the primary efficacy endpoint utilized the active control, and included comparisons
      between the placebo and active control. This study was previously posted by Sepracor Inc. In
      October 2009, Sepracor Inc. was acquired by Dainippon Sumitomo Pharma., and in October 2010,
      Sepracor Inc's name was changed to Sunovion Pharmaceuticals Inc.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">March 2004</completion_date>
  <primary_completion_date type="Actual">March 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>percent change in trough FEV1 from study baseline to the end of the dosing interval (12 hours post-second dose for the BID treatment arms and 24 hours postdose for the QD treatment arm) over the double-blind period.</measure>
    <time_frame>Weeks -2, 0, 3, 6, 9, 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>time-normalized area under the percent change from visit predose curve for FEV1 over 12 hours (nAUC0-12-P)</measure>
    <time_frame>Weeks -2, 0, 3, 6, 9, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak percent of predicted FEV1</measure>
    <time_frame>Weeks -2, 0, 3, 6, 9, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time-normalized area under the percent change in FEV1 from study baseline over 12 hours (nAUC0-12-B)</measure>
    <time_frame>Weeks -2, 0, 3, 6, 9, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time-normalized area under the percent change from visit predose curve for FEV1 over 24 hours (nAUC0-24-P)</measure>
    <time_frame>Weeks -2, 0, 3, 6, 9, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time-normalized area under the percent change in FEV1 from study baseline curve over 24 hours (nAUC0-24-B)</measure>
    <time_frame>Weeks -2, 0, 3, 6, 9, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>peak percent change in FEV1 from visit predose and study baseline</measure>
    <time_frame>Weeks -2, 0, 3, 6, 9, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time point changes in FEV1; time to onset of response</measure>
    <time_frame>Weeks -2, 0, 3, 6, 9, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to peak change in FEV1</measure>
    <time_frame>Weeks -2, 0, 3, 6, 9, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>at-home and in-clinic peak expiratory flow rate (PEFR)</measure>
    <time_frame>Weeks -2, 0, 3, 6, 9, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relationship between the plasma concentration values and selected pharmacodynamic parameters</measure>
    <time_frame>Weeks -2, 0, 3, 6, 9, 12, 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Supplemental ipratropium bromide MDI and racemic albuterol MDI use</measure>
    <time_frame>Weeks 0-13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COPD exacerbations and COPD symptom ratings</measure>
    <time_frame>Weeks 0-13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>St. George's Hospital Respiratory Questionnaire</measure>
    <time_frame>Weeks 0, 6, 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator and Subject Global Evaluations</measure>
    <time_frame>Weeks -2, 12, 13</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline and Transitional Dyspnea Index</measure>
    <time_frame>Weeks -2, 6, 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distance walked in six minutes</measure>
    <time_frame>Weeks -2, 3, 9</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">741</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <condition>Chronic Bronchitis</condition>
  <condition>Emphysema</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arformoterol 50 mcg QD and placebo MDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arformoterol 25 mcg BID and Placebo MDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arformoterol 15 mcg BID and placebo MDI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Salmeterol MDI 42 mcg BID and placebo inhalation solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo MDI and placebo inhalation solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>arformoterol tartrate inhalation solution</intervention_name>
    <description>arformoterol 50 mcg QD</description>
    <arm_group_label>1</arm_group_label>
    <other_name>(R,R)-formoterol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>arformoterol tartrate inhalation solution</intervention_name>
    <description>arformoterol 25 mcg BID</description>
    <arm_group_label>2</arm_group_label>
    <other_name>(R,R)-formoterol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>arformoterol tartrate inhalation solution</intervention_name>
    <description>arformoterol 15 mcg BID</description>
    <arm_group_label>3</arm_group_label>
    <other_name>(R,R)-formoterol</other_name>
    <other_name>Brovana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salmeterol</intervention_name>
    <description>Salmeterol MDI 42 mcg BID</description>
    <arm_group_label>4</arm_group_label>
    <other_name>Serevent MDI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo BID</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be willing to comply with study procedures and visit schedule

          -  Are at least 35 years of age

          -  Female subjects &gt;65 years of age must have a serum pregnancy test conducted at Visit 1
             and confirmed negative prior to randomization

          -  Subjects of childbearing potential must be using an acceptable method of birth
             control. Female subjects who are considered not of childbearing potential must be:
             documented surgically sterile, OR postmenopausal.

          -  Have a primary diagnosis of COPD. Diagnosis can be made during the screening process.

          -  Have a minimum smoking history of 15 pack-years (pack-years = the number of cigarette
             packs per day times the number of years).

          -  Have a chest x-ray that is consistent with the diagnosis of COPD and taken &lt;3 months
             prior to study start

          -  Able to complete all study questionnaires and logs reliably

        Exclusion Criteria:

          -  Female subject who is pregnant or lactating

          -  Have participated in an investigational drug study within 30 days prior to study
             start, or who is currently participating in another investigational drug study

          -  Subject whose schedule or travel prevents the completion of all required visits

          -  Are scheduled for in-patient hospitalization, including elective surgery during the
             trial

          -  Have life-threatening/unstable respiratory status, including upper or lower
             respiratory tract infection, within the previous 30 days

          -  History of asthma or any chronic respiratory disease other than COPD (chronic
             bronchitis and/or emphysema)

          -  Have clinically significant cardiac, hepatic, renal, gastrointestinal, endocrine,
             metabolic, neurologic, or psychiatric disorder that may interfere with successful
             completion of this protocol

          -  Have a history of cancer except non-melanomatous skin cancer

          -  Have a history of lung resection of more than one full lobe

          -  Requires continuous supplemental oxygen therapy.

          -  Has had a change in dose or type of any medications for COPD within 14 days prior to
             the screening visit

          -  Have a known sensitivity to arformoterol, ipratropium, salmeterol or albuterol or any
             of the excipients contained in any of these formulations

          -  Have a history of substance abuse or drug abuse within 12 months, or with a positive
             urine drug screen

          -  Are using any prescription drug for which concomitant beta-agonist administration is
             contraindicated (e.g., beta-blockers)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pulmonary &amp; Sleep Associates of Jasper, PC</name>
      <address>
        <city>Jasper</city>
        <state>Alabama</state>
        <zip>35501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary Associates, PA</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Clinical Research Center, Inc.</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern California Research Corp.</name>
      <address>
        <city>Fair Oaks</city>
        <state>California</state>
        <zip>95628</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SARC Research Center</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Research Medical Group, Inc.</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radiant Research-Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Coast Clinical Trials</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Trials, LLC</name>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advances in Medicine</name>
      <address>
        <city>Rancho Mirage</city>
        <state>California</state>
        <zip>92270</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Healthcare Assessment, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Jose Clinical Research</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy &amp; Asthma Medical Group of Diablo Valley, Inc.</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Pulmonary Associates</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Colorado Pulmonary Consultants, PC</name>
      <address>
        <city>Fort Collins</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physicians Research Center, Inc.</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida, Inc.</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Research, DeLand</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt. Sinai Medical Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology Services</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Protocare Trial, Inc.</name>
      <address>
        <city>Austell</city>
        <state>Georgia</state>
        <zip>30106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marietta Pulmonary Medicine</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Bradley Sakran, MD, PC</name>
      <address>
        <city>O'Fallon</city>
        <state>Illinois</state>
        <zip>62269</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Bend Clinic</name>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <zip>46617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Allergy &amp; Asthma Research Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cumberland Lung and Sleep Specialists</name>
      <address>
        <city>Somerset</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bendel Medical Associates/Research</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Best Clinical Trials, LLC</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Orleans Center for Clinical Research</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Orleans Center for Clinical Research</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Research Associates</name>
      <address>
        <city>Slidell</city>
        <state>Louisiana</state>
        <zip>70461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunset Medical Research</name>
      <address>
        <city>Sunset</city>
        <state>Louisiana</state>
        <zip>70584</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland-Airways Research Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Asthma and Allergy</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pro-Medica Clinical Research Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ClinSite, Inc.</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedEx HealthCare Research, Inc.</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Chest Consultants, PC</name>
      <address>
        <city>St. Charles</city>
        <state>Missouri</state>
        <zip>63301-2847</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.A.R.E Clinical Research</name>
      <address>
        <city>St. Louis,</city>
        <state>Missouri</state>
        <zip>63122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Keith Popovich, MD</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montana Medical Research, LLC</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Biomedical Research of America</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary Medicine</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Lung and Health Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Pharmaceutical Research, Inc.</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28625</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Hanover Medical Research</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28412</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Horizons Clinical Research, Inc.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>COR Clinical Research LLC</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Associates Research Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeast Clinical Research Centers, Inc.</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keystone Clinical Solutions</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philadelphia Health Associates - Adult Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19146</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consortium Clinical Research, Ltd.</name>
      <address>
        <city>Ridley Park</city>
        <state>Pennsylvania</state>
        <zip>19078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Safe Harbor Clinical Research</name>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <zip>02914</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spartanburg Pharmaceutical Research</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Volunteer Research Group</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Breath of Life Research Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Health Research</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sylvana Research Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary Associates of Fredericksburg, Inc.</name>
      <address>
        <city>Fredericksburg</city>
        <state>Virginia</state>
        <zip>22401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pulmonary Associates of Richmond, Inc.</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellingham Asthma, Allergy &amp; Immunology Clinic</name>
      <address>
        <city>Bellingham</city>
        <state>Washington</state>
        <zip>98225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin-Medical School</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2003</study_first_submitted>
  <study_first_submitted_qc>July 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2003</study_first_posted>
  <last_update_submitted>February 21, 2012</last_update_submitted>
  <last_update_submitted_qc>February 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Emphysema</mesh_term>
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Bronchitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

